{"name":"Gritstone bio","slug":"gritstone","ticker":"GRTS","exchange":"NASDAQ","domain":"gritstonebio.com","description":"Gritstone bio was a clinical-stage American biotechnology company which attempted to develop cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., with offices in Emeryville, California.","hq":"Emeryville, CA","founded":0,"employees":"","ceo":"Andrew Allen","sector":"Oncology / Vaccines","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":16344000,"revenueGrowth":-18.1,"grossMargin":0,"rdSpend":127182000,"netIncome":-138490000,"cash":177769000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Gritstone bio reported its financial results for the fourth quarter and full year 2022, with a net loss of $43.6 million for the quarter and $173.1 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-12-14","type":"deal","headline":"Gritstone bio Announces Collaboration with Pfizer to Develop Cancer Immunotherapies","summary":"Gritstone bio announced a collaboration with Pfizer to develop cancer immunotherapies, including a personalized neoantigen-based cancer vaccine.","drugName":"","sentiment":"positive"},{"date":"2022-09-15","type":"trial","headline":"Gritstone bio Announces Positive Interim Results from Phase 1/2 Trial of GRANITE","summary":"Gritstone bio announced positive interim results from a Phase 1/2 trial of its personalized neoantigen-based cancer vaccine, GRANITE.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2025-04-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc3JkRzhsSG1Za1NoVXFHbHEyMlpNN1dFZ2FneW5ZbGk0UlRsVUJmQkNldmJKOXZyV2pmQ3B5MGlZamJfaHE4Mk1GdFdkV0ducjgteG1EaHBRcmNzMk1GYVVxRTE5RTYtWEFPbmNJOXVUS3pEQ0o5Q0pjSXJIdGtNbWFqYzIzNVR1NUFWbXlyeEg2czJramVOVWVZay1xUHhnYm11Nk9Xem8?oc=5","date":"2025-01-06","type":"pipeline","source":"The Business Journals","summary":"Leader of failed biotech urges others to hire colleagues - San Francisco Business Times - The Business Journals","headline":"Leader of failed biotech urges others to hire colleagues - San Francisco Business Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQc1dUaE5lbVctSklMWUY3UFN4aG1BN2RsMjdJUklpUFJPX1RwTlVoM3VTOEJkemg5akRaU3Y0c2hveVVGakIxYVdCVlpnZlY3UWhLTnNEZEpwSlo5aW1HZUJuQkxMaHVLMkc3WEJhQzZJQkJtV0hDekhRZzNxZXVpX2VnaHY1VUVIZ0lqaHlGUHVVUUsyNWcxUTVXY0VuUGF1UjZsSjhZN3E4djFBdWlUYnV1czBWLUxWMzA1aEFGZ3BEcU9JZ2dta0o1c0lVU1dZ?oc=5","date":"2024-10-12","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer - Genetic Engineering and Biotechnology News","headline":"StockWatch: Investors Unfazed by Illumina’s MiSeq Product Launches, Starboard’s $1B Stake in Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQNnhZbmlqOEM0bUxReTJTallhN0Q1R3BIR3hjS3ZWbExramc3YlhOLTlwZDU3aHpKX1M0bzJBSDRSVVV5RGxEaVpMTnZLX2djTlhzd2pNVzM1SU9JTlMtaktzT01od2dTX21mTE1WUnc0bm1FdS1sRFVJUWFzN1JzQ1VDQmpkcWVYOHZkMlFNZ1BfOEljNi1oekZReUN2UWZ5YmF0bUs3N2NYaTdBVVJhbU9Gb0NzQ0hpSnp0YllsUXZGX2UwQmVlX0hyd21XV3M?oc=5","date":"2024-10-10","type":"pipeline","source":"Business Wire","summary":"Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure - Business Wire","headline":"Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iaG5Pb3FRczlPMU81ZHFnU2ZCQVBtZXI2MmdNOFJKamhTb2ZzZWpKbi1KYURRcFdEcFVPNXpKNXlKeVF6RlU5Q0tSa1drTkhKcm9WZ1hoVVVRUWxZYzExSDRRaUI1dlVOUHRPS2t3Z281VTlqLU1wa3lqQjQ?oc=5","date":"2024-10-10","type":"pipeline","source":"The Pharma Letter","summary":"Gritstone goes under after gruesome year - The Pharma Letter","headline":"Gritstone goes under after gruesome year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"Seeking Alpha","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - Seeking Alpha","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSHE1UVpIcE9oVGFEaGotVml1Sm1yOVotUWV3aDRBTmJqeWtjVXBEQjNRLXd2WlBhQXRxbVJKTnV3NDlzQVItZWVacUN2eDUzYmtzWmV5ei0xdnByOU0wWXlyMUhsRWZNeE1OcVVEWlpOUmNHYXljOFA0bllJV2JBbzFtSURRNXpycjFkNk0yMUctWDRSamF4bjBaVktvMHFHazRCdTFHQ0pGVTg?oc=5","date":"2024-04-07","type":"trial","source":"Seeking Alpha","summary":"Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering (NASDAQ:GRTS) - Seeking Alpha","headline":"Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering (NASDAQ:GRTS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOWGJaZU00TS1kNFI3RUd6STRwQnZKMVRXekZ5SkgxTGdKY0VzOC1hQWcwanhUN2ZrblhFbGdDN2tiTGRNeGU4dXJ0d1ZlMnBMUXg5OXJrd2Q4NkYzRm14ZnRxUFFKZWV1akhwSkMwRVNHNl9kM1JNdmpuTUJTbVctVVlua2Y1OXNtY2wtWjJhRHE5X0Z6QzhBX2FHYmZsWVVyWkg0WW13?oc=5","date":"2024-03-03","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Challengers Take Aim at Lilly, Novo Nordisk - Genetic Engineering and Biotechnology News","headline":"StockWatch: Challengers Take Aim at Lilly, Novo Nordisk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQMzFyVnJ6dzBsN0l6SVh1UC1DNVd1WWdlRGVKcDZYMjVoT1dWZG52YkNzSEpVdjVBVjRsNXlJcFZqVTlaM0NrV2I0VkVwQThxX3Z5SXhGMmJnd3h3WnlrZVVCRlhQQWh0YXlqVVppODNhZ2pMSTg2M2hseDRoc08wc3JQeTJ0THlQUHhzMGNnWkUzT0ZhMzhGcktrR09GYWZUNHBET3M0bUJHOXA0SjZTUURJcmozbHBGbmoxQnFlNTlGVnExZ3dUWWlB?oc=5","date":"2023-04-10","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Pharma and biotech firms announce inducement grants - drugdiscoverytrends.com","headline":"Pharma and biotech firms announce inducement grants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPa25UaHlQcVB3X3Y1OWxPUUNUVlM3S3lCbVd6ZHdPUm9NWnFFaE1nYkJOR242OEdnd0ZtS0ZFX0xtQ3IweFBoaWdLdmtSSlNURHlvcUV3WFNIbm4wS1o1VzBnTk9TX0FMZFZuUGk1cFFIY2dRQUlFWmR2S0FidlY5ekxmOHcyTHBkTGdndVFRMzR4cnk2YjNSeEdHb3NSVi1SYnM4bkdpSVZ3ZmgtcW9vcDN0c0JhSlZkd3hkd1EtbXYwNGM5Mlc5QUxoUFRPUHdLc0hoY1RNb3ZyNFp1SnpBNERhVUFWN19PNkE?oc=5","date":"2022-05-16","type":"pipeline","source":"proactiveinvestors.com","summary":"Gritstone bio shares latest clinical progress in both oncology and infectious disease - proactiveinvestors.com","headline":"Gritstone bio shares latest clinical progress in both oncology and infectious disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQQ2RWQzJfQU5fNFBwSlBMcngzbmR5dTc5R21CSGFDQ3J3Nm1CMUxSWUZJQVhIOUdCRkdKNzFrNzN4QnJtNHltOEE3dHNIc21laGhMRGVSYWNwd1BicmJjS0JXZEFZUlF3alIzUzNNVklKWkxCYU1HZ1EwOENkc01RTUNhQS1ka2ZtRVB3a0pDb3R3QdIBkgFBVV95cUxQQ2RWQzJfQU5fNFBwSlBMcngzbmR5dTc5R21CSGFDQ3J3Nm1CMUxSWUZJQVhIOUdCRkdKNzFrNzN4QnJtNHltOEE3dHNIc21laGhMRGVSYWNwd1BicmJjS0JXZEFZUlF3alIzUzNNVklKWkxCYU1HZ1EwOENkc01RTUNhQS1ka2ZtRVB3a0pDb3R3QQ?oc=5","date":"2021-09-12","type":"trial","source":"RTTNews","summary":"ESMO Congress Data Readouts: ADAP, AYLA, MGNX, DCPH... - RTTNews","headline":"ESMO Congress Data Readouts: ADAP, AYLA, MGNX, DCPH...","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology","Vaccines"],"financials":{"source":"sec_edgar+yahoo","revenue":16344000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":16344000,"period":"2023-12-31"},{"value":19945000,"period":"2022-12-31"},{"value":19945000,"period":"2022-12-31"},{"value":48214000,"period":"2021-12-31"},{"value":48214000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":127182000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-138490000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":177769000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}